185 related articles for article (PubMed ID: 21212128)
1. Silencing microRNA by interfering nanoparticles in mice.
Su J; Baigude H; McCarroll J; Rana TM
Nucleic Acids Res; 2011 Mar; 39(6):e38. PubMed ID: 21212128
[TBL] [Abstract][Full Text] [Related]
2. Interfering nanoparticles for silencing microRNAs.
Baigude H; Rana TM
Methods Enzymol; 2012; 509():339-53. PubMed ID: 22568914
[TBL] [Abstract][Full Text] [Related]
3. Strategies to antagonize miRNA functions in vitro and in vivo.
Baigude H; Rana TM
Nanomedicine (Lond); 2014 Nov; 9(16):2545-55. PubMed ID: 25490425
[TBL] [Abstract][Full Text] [Related]
4. Design and creation of new nanomaterials for therapeutic RNAi.
Baigude H; McCarroll J; Yang CS; Swain PM; Rana TM
ACS Chem Biol; 2007 Apr; 2(4):237-41. PubMed ID: 17432823
[TBL] [Abstract][Full Text] [Related]
5. Imaging Dendrimer-Grafted Graphene Oxide Mediated Anti-miR-21 Delivery With an Activatable Luciferase Reporter.
Wang F; Zhang B; Zhou L; Shi Y; Li Z; Xia Y; Tian J
ACS Appl Mater Interfaces; 2016 Apr; 8(14):9014-21. PubMed ID: 27010367
[TBL] [Abstract][Full Text] [Related]
6. Silencing of microRNAs in vivo with 'antagomirs'.
Krützfeldt J; Rajewsky N; Braich R; Rajeev KG; Tuschl T; Manoharan M; Stoffel M
Nature; 2005 Dec; 438(7068):685-9. PubMed ID: 16258535
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease.
Hartmann D; Fiedler J; Sonnenschein K; Just A; Pfanne A; Zimmer K; Remke J; Foinquinos A; Butzlaff M; Schimmel K; Maegdefessel L; Hilfiker-Kleiner D; Lachmann N; Schober A; Froese N; Heineke J; Bauersachs J; Batkai S; Thum T
Circulation; 2016 Dec; 134(24):1973-1990. PubMed ID: 27780851
[TBL] [Abstract][Full Text] [Related]
8. Delivery of MicroRNAs by Chitosan Nanoparticles to Functionally Alter Macrophage Cholesterol Efflux in Vitro and in Vivo.
Nguyen MA; Wyatt H; Susser L; Geoffrion M; Rasheed A; Duchez AC; Cottee ML; Afolayan E; Farah E; Kahiel Z; Côté M; Gadde S; Rayner KJ
ACS Nano; 2019 Jun; 13(6):6491-6505. PubMed ID: 31125197
[TBL] [Abstract][Full Text] [Related]
9. In vitro optimization of 2'-OMe-4'-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle.
Takahashi M; Yamada N; Hatakeyama H; Murata M; Sato Y; Minakawa N; Harashima H; Matsuda A
Nucleic Acids Res; 2013 Dec; 41(22):10659-67. PubMed ID: 24030710
[TBL] [Abstract][Full Text] [Related]
10. LNA-mediated microRNA silencing in non-human primates.
Elmén J; Lindow M; Schütz S; Lawrence M; Petri A; Obad S; Lindholm M; Hedtjärn M; Hansen HF; Berger U; Gullans S; Kearney P; Sarnow P; Straarup EM; Kauppinen S
Nature; 2008 Apr; 452(7189):896-9. PubMed ID: 18368051
[TBL] [Abstract][Full Text] [Related]
11. Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness.
Xie Y; Wang Y; Li J; Hang Y; Jaramillo L; Wehrkamp CJ; Phillippi MA; Mohr AM; Chen Y; Talmon GA; Mott JL; Oupický D
Theranostics; 2018; 8(16):4305-4320. PubMed ID: 30214622
[TBL] [Abstract][Full Text] [Related]
12. Anti-miRs competitively inhibit microRNAs in Argonaute complexes.
Hogan DJ; Vincent TM; Fish S; Marcusson EG; Bhat B; Chau BN; Zisoulis DG
PLoS One; 2014; 9(7):e100951. PubMed ID: 24992387
[TBL] [Abstract][Full Text] [Related]
13. Efficient in vivo microRNA targeting of liver metastasis.
Huynh C; Segura MF; Gaziel-Sovran A; Menendez S; Darvishian F; Chiriboga L; Levin B; Meruelo D; Osman I; Zavadil J; Marcusson EG; Hernando E
Oncogene; 2011 Mar; 30(12):1481-8. PubMed ID: 21102518
[TBL] [Abstract][Full Text] [Related]
14. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway.
John M; Constien R; Akinc A; Goldberg M; Moon YA; Spranger M; Hadwiger P; Soutschek J; Vornlocher HP; Manoharan M; Stoffel M; Langer R; Anderson DG; Horton JD; Koteliansky V; Bumcrot D
Nature; 2007 Oct; 449(7163):745-7. PubMed ID: 17898712
[TBL] [Abstract][Full Text] [Related]
15. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
[TBL] [Abstract][Full Text] [Related]
16. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting.
Esau C; Davis S; Murray SF; Yu XX; Pandey SK; Pear M; Watts L; Booten SL; Graham M; McKay R; Subramaniam A; Propp S; Lollo BA; Freier S; Bennett CF; Bhanot S; Monia BP
Cell Metab; 2006 Feb; 3(2):87-98. PubMed ID: 16459310
[TBL] [Abstract][Full Text] [Related]
17. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer.
Zhao Y; Zhao L; Ischenko I; Bao Q; Schwarz B; Nieß H; Wang Y; Renner A; Mysliwietz J; Jauch KW; Nelson PJ; Ellwart JW; Bruns CJ; Camaj P
Target Oncol; 2015 Dec; 10(4):535-48. PubMed ID: 25639539
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure.
Montgomery RL; Hullinger TG; Semus HM; Dickinson BA; Seto AG; Lynch JM; Stack C; Latimer PA; Olson EN; van Rooij E
Circulation; 2011 Oct; 124(14):1537-47. PubMed ID: 21900086
[TBL] [Abstract][Full Text] [Related]
19. No miRNA were found in Plasmodium and the ones identified in erythrocytes could not be correlated with infection.
Xue X; Zhang Q; Huang Y; Feng L; Pan W
Malar J; 2008 Mar; 7():47. PubMed ID: 18328111
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of microRNA with antisense oligonucleotides.
Esau CC
Methods; 2008 Jan; 44(1):55-60. PubMed ID: 18158133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
